Overview

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Hospital of Guangxi Medical University

Treatments:

Cisplatin